Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by Pj1958on May 03, 2016 9:03am
64 Views
Post# 24835987

RE:RE:RE:What Gouging?

RE:RE:RE:What Gouging?LETTUCE.... Complete nonsense. Since when have companies been responsible for what happened prior to a purchase. Another short and distort attempt to hold CXR responsible for price hikes that happened 3 years before they purchased a product.





Lattice wrote: Stockcoach et al,  There is a significant discrepancy between the price you have stated for fusidic acid eyedrops compared to the price the Financial Times has reported.  The Financial Times showed an increase of 14X (Mike Hainsworth referred to it as 1400% increase on BNN yesterday) over a three year period from £2.09 to £29.06  
 
The pricing data was collected by RxSavings Solutions, a company that analyzes prescription costs for employers (rxsavingssolutions.com). This company can not be considered a short selling organization.  

The prices of branded medications are tightly controlled in the UK, but the neat thing about AMCo's niche products is that they are generic / off-patent drugs so these large price increases have slipped through the regulatory cracks.  

Furthermore, MT has gone on record in October 2015 for saying that his stock was unfairly tarred in a sector wide price gouging scandal.  In an interview on BNN, he flaunted his sustainable growth model driven by volume.  When the price increases on these drugs took place is not relevant -
Mr. Mark Thompson should have done his due diligence with regards to how much and when AMCo took price on products in a portfolio that he had just over-paid for.
 
Adamchess, I don't feel that your "short and distort" sacred utterance is justified on ths story. I do believe that this is just one more instance of a lack of transparency by the corporation CEO.  If my haters disagree with me that is fine, as the share price is always the final arbiter of variant viewpoints.

Scruggstyle wrote:
Stockcoach1 wrote:

Fucithalmic is an ophthalmic gel containing fusidic acid for the topical treatment of bacterial infections.
 
Concordia's Branded US prices- 10mg 5 gram tube $12.69 USD, without prescription $25.00 USD.
 
Concordia's Branded UK prices- 10mg 5 gram tube from £2.69-£6.92
 
 
Polysporin Eye and Ear drops in Canada around 10.00 - 17.00. 
Had Polysporin prescribed in the US and they cost me $96.00 USD over 10 years ago. 
 
Can't say that Concordia is gouging, they are not even close to the average prices. Don't forget this is a one time prescription, not something you need re-prescribed.

Even ordinary over the counter eye drops cost more than that.


Absolutely correct, thank you for the post!




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse